The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
ENERZAIR BREEZHALER (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
ENERZAIR BREEZHALER
Date registered
Evaluation commenced
Decision date
Approval time
226 working days (255)
Active ingredients
glycopyrronium bromide; indacaterol acetate; mometasone furoate
Registration type
EOI
Indication
New Combination
ENERZAIR BREEZHALER (hard capsule) is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.